Presented by

Prof. Dr. Karl-Josef Langen, MD

Institute of Neuroscience and Medicine
Forschungszentrum Jülich
Clinic of Nuclear Medicine
RWTH University Hospital Aachen

Dr Karl-Josef Langen is a nuclear medicine physician focused on preclinical and clinical testing of new radiopharmaceuticals for nuclear medicine diagnostics. He qualified at RWTH Aachen University Clinic in 1985 and completed training in nuclear medicine at the University of Düsseldorf in 1989. After habilitation in nuclear medicine in 1992 he became head of a research group at the Research Center Jülich (FZJ) focusing on SPECT/PET and correlative MR-PET imaging of brain tumors including Hybrid-PET-MRI. In 2013 he was appointed professor and senior physician of the Department of Clinical and Experimental Nuclear Medicine at the RWTH Aachen University at the research center Jülich.

The main focus of the scientific work of Dr Langen is the use of radiolabeled amino acids for the diagnosis of brain tumors. This includes the evaluation of transport mechanisms of amino acids in cell cultures and tissue probes, the assessment of intratumoral accumulation in experimental rat gliomas and other brain lesions by autoradiography and animal PET as well as amino acid uptake in human brain tumors using PET in correlation with modern developments of functional MRI and the clinical application of correlative MR-PET imaging for the diagnosis, therapy planning and therapy control in patients with brain tumors.

Brain Tumor Imaging Using Amino Acid PET

This program is designed with the following educational objectives:

  1. Review of uptake mechanisms of amino acid tracers and the additional information provided by amino acid PET in relation to conventional MRI.
  2. Deliver insights into the clinical benefits of FET PET in the assessment of newly diagnosed brain tumors.
  3. Describe the use of FET PET in the differentiation of tumor progression and treatment-related changes in pretreated gliomas and brain metastases.
  4. Explain the advantages of FET PET in treatment monitoring of cerebral gliomas.
View Program